EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset

Martin Chandler, Thomas Moulton, Lena Charafi, Jessica Charlet, Michael Recht

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Martin Chandler und 4 weiteren Autor:innen. Beteiligte Einrichtung: American Thrombosis & Hemostasis Network, Rochester, New York, USA. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Health information for 17 109 people living with hemophilia A (PLwHA) is contained within the ATHNdataset. We aimed to evaluate the real‐world effectiveness of damoctocog alfa pegol (BAY 94‐9027, Jivi®) for hemophilia A.

Methods

The ATHNdataset was queried for PLwHA receiving damoctocog alfa pegol between January 1, 2010 and April 30, 2022. Data captured via patient charts were analyzed.

Results

At data cutoff, 205 PLwHA were treated with damoctocog alfa pegol: 150 (73.2%) severe (1 female [0.5%]) and 55 (26.8%) mild/moderate (3 [1.5%] female). In total, 32/205 (25.9%) PLwHA received on‐demand treatment; 172 (83.9%) received prophylaxis—161 (93.6%) continuous prophylaxis. Documented bleed rates were available for 187 (91.2%) PLwHA, including those on prophylaxis and on‐demand regimens, with 150 (80.2%) treated for > 12 months. Overall annualized bleeding rates and proportion of PLwHA with zero bleeds, receiving prophylaxis during the observation period, were mean (SD) 0.26 (1.03) and 138/157 (87.9%), respectively. No new or recurring inhibitors were reported.

Conclusion

A low number of bleeds were observed with damoctocog alfa pegol in the real world in both male and female PLwHA. Data should be interpreted with caution owing to limitations of real‐world studies and insubstantial data for female PLwHA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AFactor VIIIHumansFemaleMaleAdultTreatment OutcomeMiddle AgedHemorrhageAdolescentYoung AdultChildAged

Stichwörter der Autor:innen

ATHNdatasetJividamoctocog alfa pegolextended half‐lifehemophilia Areal‐worldrecombinant factor FVIII

Substanzen

Factor VIII

Autor:innen und Institutionen

  • American Thrombosis & Hemostasis Network, Rochester, New York, USA.
  • Bayer U.S. LLC, Whippany, New Jersey, USA.
  • Yale University School of Medicine, New Haven, Connecticut, USA.

Förderung

  • Bayer

Zitieren

APA

Chandler, M., Moulton, T., Charafi, L., Charlet, J., & Recht, M. (2025). Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset. European Journal of Haematology. https://doi.org/10.1111/ejh.14337

Vancouver

Chandler M, Moulton T, Charafi L, Charlet J, Recht M. Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset. European Journal of Haematology. 2025. doi:10.1111/ejh.14337

BibTeX
@article{Chandler2025,
  author = {Chandler, Martin and Moulton, Thomas and Charafi, Lena and Charlet, Jessica and Recht, Michael},
  title = {Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14337}
}
Kostenlos starten →